Astrana Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 1, 2025, reports the completion of a major acquisition by Astrana Health, Inc. (ASTH). The transaction closed on July 1, 2025, involving the purchase of all outstanding equity interests of Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center) and Prospect Health Plan, Inc., along with substantially all assets of certain subsidiaries of PHP Holdings, LLC.
Key Financial Metrics and Transaction Details
- Purchase Price: The aggregate purchase price was reduced to $707.9 million in cash, down from an initial $745.0 million, pursuant to a Letter Agreement entered into at closing.
- Financing: The transaction was financed using $707.9 million in proceeds from a five-year delayed draw term loan credit facility under the Second Amended and Restated Credit Agreement dated February 26, 2025.
- Liabilities: The Company assumed certain identified liabilities of the Sellers as part of the transaction.
- Financial Results: The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period. It references a press release (Exhibit 99.1) for updated full-year 2025 revenue and adjusted EBITDA guidance, but the specific numbers are not contained in this text.
Material Changes and Adjustments
The primary material change is the reduction of the aggregate purchase price from $745.0 million to $707.9 million. Additionally, the Letter Agreement removed certain post-closing purchase price adjustments and related escrow provisions. The Company entered into a transition services agreement with the Sellers to provide post-closing support.
Guidance, Outlook, and Risks
On July 2, 2025, the Company issued a press release reaffirming its second-quarter guidance and updating its full-year 2025 revenue and adjusted EBITDA guidance. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks including:
- Diversion of management attention from ongoing operations.
- Increased costs, fees, and expenses related to the transaction.
- Business disruption and employee retention challenges.
- The Company's ability to service debt under the Second Amended and Restated Credit Agreement.
- Uncertainty in realizing the intended benefits of the transaction.
Pro forma financial information and financial statements of the acquired businesses are not included in this filing and are expected to be filed within 71 days.
Key Facts for Investor Verification
- Verify the specific updated full-year 2025 revenue and adjusted EBITDA guidance figures in the press release (Exhibit 99.1) referenced in Item 2.02.
- Review the full text of the Second Amended and Restated Credit Agreement (Exhibit 10.1) to understand debt covenants and repayment terms.
- Monitor the upcoming filing (within 71 days) for the financial statements of the acquired businesses and pro forma financial information.
- Assess the impact of the $707.9 million cash outflow and assumed liabilities on the Company's liquidity and leverage ratios.